Resultado de búsqueda
28 de ene. de 2021 · The mechanism responsible for hypoglycaemia induced by β-blockers has not been elucidated. Drug rankings may guide β-blockers switching toward metabolically safer drugs, improving appropriate prescribing and use of these agents; however, the rank order has not been characterised. What this study adds.
1 de ago. de 2011 · β-blockers can cause or exacerbate hypoglycemia in some individuals, either by worsening an already present hypoglycemic episode or by delaying recovery time. 17 The mechanism responsible for β-blocker–induced hypoglycemia involves inhibition of hepatic glucose production, which is promoted by sympathetic nervous stimulation.
27 de nov. de 2019 · Beta blocker use is associated with increased odds of hypoglycemia among hospitalized patients not requiring basal insulin, and odds are greater for selective beta blockers than for carvedilol.
30 de may. de 2017 · The role of β-blockers on patients with a diagnosis of diabetes mellitus is controversial. They have been considered time-to-time neutral or able to induce hypoglycemia or, on the contrary, hyperglycemia. Physicians learned early in the β-blocking era to fear the reduction of the peripheral effects of hypoglycemia that accompanied β-blockade ...
Nadolol appears to be the β-blocker significantly most associated with hypoglycaemia and children represent the most susceptible sample. Furthermore, long half-life and nonselective β-blockers seem to increase the risk for its occurrence.
Results: Beta-blockers differ in terms of their mechanism of action and their effects on glucose and lipid metabolism. Nonvasodilating beta-blockers reduce blood pressure in association with a cardiac output reduction and may increase or have no appreciable effect on peripheral vascular resistance.
27 de nov. de 2019 · Conclusions: Beta blocker use is associated with increased odds of hypoglycemia among hospitalized patients not requiring basal insulin, and odds are greater for selective beta blockers than for carvedilol.
